Pilot study of GW786034 (pazopanib), a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with operable breast cancer.
Phase of Trial: Phase 0
Latest Information Update: 13 Dec 2013
At a glance
- Drugs Pazopanib (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 13 Dec 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 14 Dec 2012 Status changed from discontinued to active, no longer recruiting as reported by ClinicalTrials.gov.